Publications by authors named "A L Stebbins"
Article Synopsis
- Tricuspid regurgitation (TR) is linked to poorer health outcomes after procedures like TAVR and M-TEER, emphasizing the need to understand its impact on patient health status.
- The study analyzed data from a large registry to explore the relationship between levels of baseline TR and health status, measured through KCCQ-OS scores, as well as clinical outcomes post-procedure.
- Results indicated that patients with moderate to severe TR before intervention had significantly lower health scores and higher risks for mortality and readmission after 1 year compared to those with none to mild TR.
Article Synopsis
- - Atherosclerotic cardiovascular disease (ASCVD) is the main health issue in the US, and while aspirin is commonly used for its prevention, a trial (ADAPTABLE) found no significant difference in outcomes between 81 mg and 325 mg doses of aspirin.
- - The study aimed to investigate whether there are differences in safety and effectiveness of the two aspirin doses based on sex, as previous findings didn't address this.
- - Conducted across multiple medical centers, the ADAPTABLE trial involved over 15,000 participants with established ASCVD, analyzing outcomes related to major bleeding, heart attacks, and strokes, with a focus on comparing male and female responses to the aspirin doses.
Article Synopsis
- Hypertensive disorders of pregnancy (HDP) increase the risk of cardiovascular disease, and guidelines suggest these women should be screened for hypertension within 6-12 months after giving birth.* -
- A study found that only 28% of women with HDP underwent early blood pressure screening, with certain factors like older age and pre-existing health conditions influencing the likelihood of early screening.* -
- Women who received early screening were more likely to have cardiovascular risk factors detected compared to those screened later (56% vs 28%), highlighting the need for improved postpartum screening practices.*
Aims: Type 2 diabetes (T2D) is a risk factor for cardiovascular and non-cardiovascular mortality. However, global distribution of cause-specific deaths in T2D is poorly understood. We characterized cause-specific deaths by geographic region among individuals with T2D at risk for cardiovascular disease (CVD).
View Article and Find Full Text PDFArticle Synopsis
- The VICTORIA study found that vericiguat reduced the risk of cardiovascular death or heart failure hospitalization compared to a placebo in patients with heart failure having reduced ejection fraction.
- The research evaluated how vericiguat impacted the frequency of hospitalizations for heart failure and subsequent mortality, using patient data to analyze various factors.
- Results showed a slight benefit of vericiguat in patients with lower levels of a specific biomarker (N-terminal pro-B-type natriuretic peptide), but overall, the differences in mortality rates were not significant between the vericiguat and placebo groups.